Key facts
- Precede Biosciences’s last known valuation is $198.5M (Oct 2025).
- It has raised $132.0M; the latest was Later Stage VC ($83.5M) in Oct 2025.
- Notable investors include Alexandria Venture Investments, Mirae Asset Capital, Qatar Investment Authority, Osage University Partners, Labcorp Venture Fund — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Precede Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Precede Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Precede Biosciences
Developer of a liquid biopsy platform designed to provide resolution into disease-defining biology from a blood test. The company's platform profiles circulating chromatin and the DNA methylome from plasma, enabling researchers and clinicians to gain insight into the activation of individual genes and pathways in diseased tissues.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 48
- Website
- precede.bio/
- Ownership
- Privately Held (backing)
Precede Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Precede Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Precede Biosciences in its N-PORT filings yet. We sweep new filings monthly.